ATE553098T1 - Verfahren zur herstellung von rosuvastatin- calcium - Google Patents

Verfahren zur herstellung von rosuvastatin- calcium

Info

Publication number: ATE553098T1
Authority: AT; Austria
Prior art keywords: rosuvastatin calcium; producing rosuvastatin; producing; calcium; dihydroxyhept
Prior art date: 2007-02-08

Application number

AT08702369T

Other languages

English (en)

Inventor

Ramesh Dandala

Sambhu Prasad Sarma Mallela

Sukumar Nandi

Gangadhar Bhima Shankar Nangi

Sunil Kumar Buridipadu

Sivakumaran Meenakshisunderam

Original Assignee

Aurobindo Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-08

Filing date

2008-02-04

Publication date

2012-04-15

2008-02-04 Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE553098T1 publication Critical patent/ATE553098T1/de

Links

238000004519 manufacturing process Methods 0.000 title abstract 2
229960004796 rosuvastatin calcium Drugs 0.000 title 1
LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 title 1
AVDMILNVMOXCHF-DHMAKVBVSA-N calcium;(e,3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound [Ca].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O AVDMILNVMOXCHF-DHMAKVBVSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT08702369T 2007-02-08 2008-02-04 Verfahren zur herstellung von rosuvastatin- calcium ATE553098T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN277CH2007		2007-02-08
IN1121CH2007		2007-05-29
PCT/IB2008/000290 WO2008096257A1 (en)	2007-02-08	2008-02-04	An improved process for preparation of rosuvastatin calcium

Publications (1)

Publication Number	Publication Date
ATE553098T1 true ATE553098T1 (de)	2012-04-15

Family

ID=39323006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08702369T ATE553098T1 (de)	2007-02-08	2008-02-04	Verfahren zur herstellung von rosuvastatin- calcium

Country Status (7)

Country	Link
US (1)	US8212035B2 (de)
EP (1)	EP2125754B1 (de)
AT (1)	ATE553098T1 (de)
AU (1)	AU2008212622B2 (de)
CA (1)	CA2677809A1 (de)
ES (1)	ES2385623T3 (de)
WO (1)	WO2008096257A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6835838B2 (en) *	2002-01-28	2004-12-28	Novartis Ag	Process for the manufacture of organic compounds
US7851624B2 (en)	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
EP2093230A1 (de)	2007-04-18	2009-08-26	Teva Pharmaceutical Industries Ltd.	Verfahren zur Herstellung von Zwiechenverbindungen von HMG-CoA reductase Inhibitoren
WO2010071595A1 (en) *	2008-12-19	2010-06-24	Sekab Biofuels & Chemicals Ab	Denaturant-containing, ethanol-based liquid
US9701642B2 (en)	2013-08-30	2017-07-11	Nissan Chemical Industries, Ltd.	Method for producing optically active 5-hydroxy-3-ketoester

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
GB9903472D0 (en)	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
US6872715B2 (en) *	2001-08-06	2005-03-29	Kosan Biosciences, Inc.	Benzoquinone ansamycins
GB0204129D0 (en)	2002-02-21	2002-04-10	Novartis Ag	Process for the manufacture of organic compounds
AR039836A1 (es)	2002-05-21	2005-03-02	Ranbaxy Lab Ltd	Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
CN1742000A (zh)	2002-12-10	2006-03-01	兰贝克赛实验室有限公司	制备若舒伐他汀的方法
CA2537271A1 (en)	2003-08-28	2005-03-17	Teva Pharmaceutical Industries, Ltd.	Process for preparation of rosuvastatin calcium
CN1886383A (zh)	2003-10-22	2006-12-27	兰贝克赛实验室有限公司	无定形罗苏伐他汀钙的制备方法
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
WO2005051921A1 (en)	2003-11-24	2005-06-09	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
US20080234302A1 (en)	2004-09-27	2008-09-25	Mohammad Rafeeq	Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
US20070167625A1 (en)	2005-02-22	2007-07-19	Anna Balanov	Preparation of rosuvastatin
CA2683975A1 (en)	2005-02-22	2006-08-31	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en)	2005-02-22	2007-02-15	Valerie Niddam-Hildesheim	Preparation of rosuvastatin
EP1863773A1 (de)	2005-03-22	2007-12-12	Unichem Laboratories Limited	Verfahren zur herstellung von rosuvastatin
EP1869005A1 (de)	2005-04-04	2007-12-26	Unichem Laboratories Limited	Verfahren zur herstellung des calciumsalzes von rosuvastatin
EP2508514B1 (de)	2005-06-24	2017-10-18	LEK Pharmaceuticals d.d.	Verfahren zur Herstellung von amorphem Rosuvastatincalcium frei von Verunreinigungen
ES2564807T5 (es)	2005-06-24	2019-02-26	Lek Pharmaceuticals	Proceso para preparación de rosuvastatina de calcio amorfa pura
CZ299215B6 (cs)	2005-06-29	2008-05-21	Zentiva, A. S.	Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en)	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
EP1912953B1 (de)	2005-07-28	2016-08-17	LEK Pharmaceuticals d.d.	Verfahren zur synthese von rosuvastatin-calcium
US20070099994A1 (en)	2005-08-16	2007-05-03	Valerie Niddam-Hildesheim	Rosuvastatin calcium with a low salt content
BRPI0606170A2 (pt)	2005-10-03	2009-06-02	Teva Pharma Ltd	purificação diastereomérica de rosuvastatina
WO2007099561A1 (en)	2006-02-27	2007-09-07	Cadila Healthcare Limited	Process for preparing rosuvastatin calcium
US8404841B2 (en)	2006-10-09	2013-03-26	Msn Laboratories Limited	Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (de)	2007-08-08	2009-02-11	LEK Pharmaceuticals D.D.	Verfahren zur Herstellung des Methylesters von Rosuvastatin
HU230637B1 (hu)	2007-10-12	2017-05-29	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Eljárás rosuvastatin intermedierek előállítására

2008
- 2008-02-04 CA CA002677809A patent/CA2677809A1/en not_active Abandoned
- 2008-02-04 EP EP08702369A patent/EP2125754B1/de not_active Not-in-force
- 2008-02-04 US US12/449,426 patent/US8212035B2/en not_active Expired - Fee Related
- 2008-02-04 WO PCT/IB2008/000290 patent/WO2008096257A1/en not_active Ceased
- 2008-02-04 AU AU2008212622A patent/AU2008212622B2/en not_active Ceased
- 2008-02-04 AT AT08702369T patent/ATE553098T1/de active
- 2008-02-04 ES ES08702369T patent/ES2385623T3/es active Active

Also Published As

Publication number	Publication date
AU2008212622A1 (en)	2008-08-14
AU2008212622B2 (en)	2011-01-27
CA2677809A1 (en)	2008-08-14
ES2385623T3 (es)	2012-07-27
EP2125754A1 (de)	2009-12-02
WO2008096257A1 (en)	2008-08-14
EP2125754B1 (de)	2012-04-11
US20090312547A1 (en)	2009-12-17
US8212035B2 (en)	2012-07-03

Similar Documents

Publication	Publication Date	Title
TWI341310B (en)	2011-05-01	Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
MY142615A (en)	2010-12-15	Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
IS8478A (is)	2006-05-22	Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
JOP20190231B1 (ar)	2024-04-18	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2009157014A3 (en)	2010-07-22	A process for preparing hmg-coa reductase inhibitors and intermediates
EE05288B1 (et)	2010-04-15	7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad
DK1144389T3 (da)	2005-02-14	Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt
EA201070410A1 (ru)	2010-10-29	Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
ATE501126T1 (de)	2011-03-15	Verfahren zur herstellung von rosuvastatin
MY180039A (en)	2020-11-20	N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
DE602007008691D1 (de)	2010-10-07	Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind
UA112423C2 (uk)	2016-09-12	Спосіб одержання (варіанти) кристалічних форм розувастатину тба
DE602004004679D1 (de)	2007-03-22	Verfahren zur herstellung des hemicalciumsalzes von (e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-ämethyl(methylsulfonyl)aminoüpyrimidin-5-ylü(3r,5s)-3,5-dihydroxy-6-heptensäure
NZ611072A (en)	2014-10-31	Method for preparing rosuvastatin salts
MX2010011006A (es)	2012-04-18	Nueva sal de un derivado de pirimidina.
TR200800269A2 (tr)	2009-08-21	Stabil farmasötik formülasyon ve hazırlama yöntemleri
AR043594A1 (es)	2005-08-03	Un procedimiento para la preparacion de la sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metil-sulfonil)amino]pirimidin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y compuesto utilizable en dicho procedimiento